Bristol Myers Squibb™

NICE MEDIA RELEASE FOR USE IN UK MEDICAL, TRADE & CONSUMER MEDIA EMBARGOED UNTIL 28th JUNE 2023 00:01

Sotyktu™▼ (deucravacitinib) recommended for use on the NHS in England as a first-in-class treatment option for moderate to severe plaque psoriasis in adults

- *Deucravacitinib has been recommended by the National Institute for Health and Care Excellence (NICE) for use in England for the treatment of certain adults with moderate to severe plaque psoriasis who are candidates for systemic therapy*[1,2]

- *Psoriasis is a chronic skin condition that is estimated to affect up to 1.8 million people in the UK*[3]

(Uxbridge, Middlesex, 28th June 2023) - Bristol Myers Squibb (BMS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet, for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis. Specifically, this guidance means that deucravacitinib will be available to these patients if: the Psoriasis Area and Severity Index (PASI) is 10 or more and the Dermatology Life Quality Index (DLQI) is more than 10; and if the condition has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated.[1,2] This recommendation from NICE follows receipt of marketing authorisation in Great Britain on 10th May 2023 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.[2]

Psoriasis is a common skin condition that affects approximately 2-3% of the UK population and can have a significant impact on people's physical and mental wellbeing.[3] There are numerous comorbidities associated with psoriasis, including psoriatic arthritis, cardiovascular disease, metabolic syndrome, depression, and anxiety. The challenges associated with living with a visible disease, as well as the social stigma that can be experienced, can take a significant toll on patients' emotional and social well-being.[4]

Professor Chris Griffiths, Emeritus Professor, University of Manchester commented: *"Today's announcement marks another step forward for people with psoriasis. This complex condition can affect each person differently, therefore, it is my hope that access to a greater variety of treatments, such as deucravacitinib, will enable eligible patients to have more choice, with therapies that may suit their daily needs and lifestyle."*

The UK has played an important role in the research and development of deucravacitinib. The BMS site in Moreton, located in the north-west of England, was involved in the CMC (Chemistry, Manufacturing and Controls) development of deucravacitinib from 2015, and collaborated with world-leading academic institutions in the UK on the science behind the medicine. Patients in the UK have also been amongst the first to have benefited from this drug, due to the UK's active involvement within deucravacitinib's global clinical trial programme.[5,6]

Laura Stevenson, Deputy Chief Executive at Psoriasis Association commented: *"It is estimated that psoriasis affects over a million people across the UK and for some, it can have a significant*

life impact. It is therefore hugely important for the community to have access to a variety of treatments, including new therapies such as deucravacitinib. The availability of deucravacitinib for adults with moderate to severe plaque psoriasis may make a real difference for eligible people with psoriasis and add to their potential treatment options. The Psoriasis Association is a national charity, here to provide patients with important new information as well as support with their condition."

- ENDS -

Notes to editors

About Deucravacitinib

Deucravacitinib (pronounced doo-krav-a-sih-ti-nib) is a selective allosteric tyrosine kinase 2 (TYK2) inhibitor. Bristol Myers Squibb scientists designed deucravacitinib to selectively target TYK2, thereby mediating signalling of interleukin (IL)-23 and Type 1 interferons (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases. Deucravacitinib achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions.[7,8]

Bristol Myers Squibb: Pioneering Paths Forward in Immunology to Transform Patients' Lives

Bristol Myers Squibb is inspired by a single vision – transforming patients' lives through science. For people living with immune-mediated diseases, the reality of enduring chronic symptoms and disease progression can take a toll on their physical, emotional and social well-being, making simple tasks and daily life a challenge. Driven by our deep understanding of the immune system that spans over 20 years of experience, and our passion to help patients, the company continues to pursue pathbreaking science with the goal of delivering meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and multiple sclerosis. We follow the science, aiming to tailor therapies to individual needs, improve outcomes and expand treatment options by working to identify mechanisms with the potential to achieve long-term remission in the future. By building partnerships with researchers, patients and caregivers to deliver innovative treatments, Bristol Myers Squibb strives to elevate patient care to new standards and deliver what matters most – the promise of living a better life.

Media Contacts:

Jane Speight
Bristol-Myers Squibb Pharmaceuticals Limited
T: 01895 523000
E: Jane.Speight@bms.com

Katy Foy
akt health communications
T: +44 (0)7794 700 151
E: katy@akthealthcomms.com

References

[1] National Institute for Health and Care Excellence. Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]. Available at: https://www.nice.org.uk/guidance/awaiting-development/gid-ta10855. Last Accessed: June 2023.

[2] Deucravacitinib Summary of Product Characteristics.

[3] About Psoriasis. (n.d.). Psoriasis Association. Available at https://www.psoriasis-association.org.uk/about-psoriasis. Last Accessed: June 2023.

[4] Michalek, I. M., Loring, B. & John, S. M. Global report on psoriasis. (2016). Geneva, Switzerland: World Health Organization. Last Accessed: June 2023.

[5] ClinicalTrials.gov. Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis (POETYK-PSO-1). Available at https://clinicaltrials.gov/ct2/show/NCT03624127. Last Accessed: June 2023.

[6] ClinicalTrials.gov. An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (POETYK-PSO-2). Available at https://clinicaltrials.gov/ct2/show/NCT03611751. Last Accessed: June 2023.

[7] Armstrong, A. et al, Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial, J Am Acad Dermatol January 2023, Volume 88, Number 1, Pages 29-39. Last Accessed: June 2023.

[8] Strober, B. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial, J Am Acad Dermatol, January 2023, Volume 88, Number 1, Pages 40-51. Last Accessed: June 2023.